N-hydroxy-2-(4-iodo-phenyl)-ethanamidine | 176860-58-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-hydroxy-2-(4-iodo-phenyl)-ethanamidine
• 英文别名: N-hydroxy-2-(4-iodo-phenyl)-acetamidine；N'-hydroxy-2-(4-iodophenyl)ethanimidamide
• CAS: 176860-58-5
• 化学式: C₈H₉IN₂O
• 分子量: 276.077
• InChiKey: NHLDVXLYCNARNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-hydroxy-2-(4-iodo-phenyl)-ethanamidine 在 吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 Phosphoric acid mono-[4-((S)-2-acetylamino-2-{(S)-2-hydroxy-1-[3-(4-iodo-benzyl)-[1,2,4]oxadiazol-5-yl]-ethylcarbamoyl}-ethyl)-phenyl] ester
  参考文献：
  名称：

  Discovery of Potent and Selective SH2 Inhibitors of the Tyrosine Kinase ZAP-70

  摘要：

  A series of 1,2,4-oxadiazole analogues has been shown to be potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70, a potential therapeutic target for immune suppression. These compounds typically are 200-400-fold more potent than the native, monophosphorylated tetrapeptide sequences. When compared with the high-affinity xi-1-ITAM peptide (Ac-NQL-pYNELNLGRREE-pYDVLD-NH2, wherein pY refers to phosphotyrosine) some of the best 1,2,4-oxadiazole analogues are approximately 1 order of magnitude less active. This series of compounds displays an unprecedented level of selectivity over the closely related tyrosine kinase Syk, as well as other SH2-containing proteins such as Src and Grb2. Gel shift studies using a protein construct consisting only of C-terminal ZAP-70 SH2 demonstrate that these compounds can effectively engage this particular SH2 domain.

  DOI：

  10.1021/jm990229t
• 作为产物：
  描述：

  4-碘苯基乙腈, 在 sodium hydroxide 、 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 48.0h， 生成 N-hydroxy-2-(4-iodo-phenyl)-ethanamidine
  参考文献：
  名称：

  Discovery of Potent and Selective SH2 Inhibitors of the Tyrosine Kinase ZAP-70

  摘要：

  A series of 1,2,4-oxadiazole analogues has been shown to be potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70, a potential therapeutic target for immune suppression. These compounds typically are 200-400-fold more potent than the native, monophosphorylated tetrapeptide sequences. When compared with the high-affinity xi-1-ITAM peptide (Ac-NQL-pYNELNLGRREE-pYDVLD-NH2, wherein pY refers to phosphotyrosine) some of the best 1,2,4-oxadiazole analogues are approximately 1 order of magnitude less active. This series of compounds displays an unprecedented level of selectivity over the closely related tyrosine kinase Syk, as well as other SH2-containing proteins such as Src and Grb2. Gel shift studies using a protein construct consisting only of C-terminal ZAP-70 SH2 demonstrate that these compounds can effectively engage this particular SH2 domain.

  DOI：

  10.1021/jm990229t

文献信息

• [EN] HYDROXAMID ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE UTILISES COMME INHIBITEURS DE L'HISTONE DESACETYLASE (HDAC)
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004063169A1

  公开（公告）日：2004-07-29

  A compound having the following formula (I): wherein R1 is N-containing heterocyclic ring optionally substituted with one or more suitable substituent(s), R2 is hydroxyamino, R3 is hydrogen or a suitable substituent, L1 is -(CH?2#191)?n#191- (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), wherein one or more methylene(s) may be replaced with suitable heteroatom(s), and L2 is lower alkenylene, or a salt thereof. The compound is useful as a histone deacetylase inhibitor.

  具有以下化学式（I）的化合物：其中R1是N-含杂环环，可选择地取代一个或多个适当的取代基，R2是羟胺基，R3是氢或适当的取代基，L1是-(CH?2#191)?n#191-（其中n是0到6的整数），可选择地取代一个或多个适当的取代基，其中一个或多个亚甲基可以被适当的杂原子取代，L2是较低的烯烃基，或其盐。该化合物可用作组蛋白去乙酰化酶抑制剂。
• HDAC inhibitor
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040229889A1

  公开（公告）日：2004-11-18

  A compound having the following formula (I): 1 wherein R 1 is N-containing heterocyclic ring optionally substituted with one or more suitable substituent(s), R 2 is hydroxyamino, R 3 is hydrogen or a suitable substituent, L 1 is —(CH 2 ) n — (wherein n is an integer of 0 to 6) optionally substituted with one or more suitable substituent(s), wherein one or more methylene(s) may be replaced with suitable heteroatom(s), and L 2 is lower alkenylene, or a salt thereof. The compound is useful as a histone deacetylase inhibitor.

  具有以下化学式（I）的化合物： 其中 R1是N-含氮杂环环，可选地取代一个或多个适当的取代基， R2是羟胺基， R3是氢或适当的取代基， L1是—(CH2)n—（其中n是0到6的整数），可选地取代一个或多个适当的取代基，其中一个或多个亚甲基可以被适当的杂原子取代，以及 L2是较低的烯烃基， 或其盐。该化合物可用作组蛋白去乙酰化酶抑制剂。
• Potentiators Of Glutamate Receptors
  申请人：AICHER Thomas Daniel

  公开号：US20090318481A1

  公开（公告）日：2009-12-24

  This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.

  本申请涉及一种公式I的取代羟基苯酮化合物，或其药学上可接受的盐，及其在治疗偏头痛中的应用，以及制备公式I化合物的过程和其中有用的中间体化合物的应用。
• Potentiators of glutamate receptors
  申请人：Eli Lilly and Company

  公开号：US07803938B2

  公开（公告）日：2010-09-28

  This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.

  本申请涉及一种I式置换羟基苯酮化合物，或其药学上可接受的盐，以及其在治疗偏头痛中的应用的制药组合物。本申请还涉及制备I式化合物的过程以及其中有用的中间体化合物。
• Potentiators of Glutamate Receptors
  申请人：Eli Lilly and Company

  公开号：EP2441762A1

  公开（公告）日：2012-04-18

  The present invention provides compounds of formula I: pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.

  本发明提供了式 I 的化合物： 其药物组合物、使用方法、制备方法及其中间体。